How efficacious is SHINGRIX?
SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.4,5,7,8
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Risks in ageing immune systems and compromised immune systems.
Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.5,6
Efficacy and Safety data in age 50+ Immunocompetent populations.
SHINGRIX has a clinically acceptable safety and tolerability profile.1-4
Efficacy and Safety data in 18+ Immunocompromised populations.
SHINGRIX has demonstrated efficacy in two immunocompromised (IC) patient populations ≥18 years of age (includes post-hoc analyses).1,2
Dosing schedule, administration, contraindications, storage, reconstitution and availability information.
SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: adults 50 years of age or older; adults 18 years of age or older at increased risk of HZ.1,2
Shingrix availability in the UK and considerations on where the most effective place to vaccinate different patient populations could be, including those within the Shingles National Programme, those 50+ and Immunocompromised patients.8
Get the information you need to administer SHINGRIX to adults 50 years of age and older with confidence.1,2
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
September 2022 | PM-GB-SGX-WCNT-220010 (V1.0)